Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — Investor Day (September 2008)
16 slides from Teva Pharmaceutical Industries's investor day presentation, Sep 9, 2008
Slide 1: Rolling Out Our GGR Strategy
Rolling Out Our GGR Strategy Jacob Winter, Global Generic Resources September 9, 2008 Jerusalem
Slide 2: Key Themes
Key Themes Goal Goal of of Global Global Enable Enable Teva Teva to to win win Generic in in all all markets markets where where Generic we Resources Resources we compete compete
Slide 3: Key Pillars of Our Strategy
Key Pillars of Our Strategy Increase Increase Teva’s Teva’s Extend leadership in U.S. market market share share in in Establish leadership in key EU and International markets key key markets markets Double R&D capabilities Double Double our our Focus on first-to-market / Paragraph IVs product produc
Slide 4: Key Pillars of Our Strategy: Achieve 2x Submissions
Key Pillars of Our Strategy Achieve 2x Submissions Globalize and Integrate product selection Increase Increase Teva’s Teva’s Develop Earlier market market share share in in key key markets markets Strengthen Scientific Know-how Establish Regional Managers: US, EU, International Double Double our our
Slide 5: Teva Global Generic R&D Sites
Teva Global Generic R&D Sites 3 $!$ 45 " , " ! -/ - ./ & 2 $( ( 0 ) 0 1 % & % ' ( ) * ! + $ " # $ $ !
Slide 6: Global Portfolio Uses U.S. as Springboard
Global Portfolio Uses U.S. as Springboard 6778 6747 ( < < ( ! 9 : $ 465 ! 1 : ! ! 1 = # > ( $! $ 1 ! ' % ;" ! % % : ' ! $$ $! * ' ' !( != ! ! ! ?!$
Slide 7: What Makes Teva Generic R&D Successful
What Makes Teva Generic R&D Successful Truly globalized Generic R&D People and management experience Legal and regulatory expertise Leveraging files between markets Vertical integration with Teva API Teva is a preferred customer (API vendors, CRO’s)
Slide 8: Key Pillars of Our Strategy
Key Pillars of Our Strategy Increase Increase Teva’s Teva’s Extend leadership in U.S. market market share share in in Establish leadership in key EU and International markets key key markets markets Double R&D capabilities Double Double our our Focus on first-to-market / Paragraph IVs product produc
Slide 9: Key Pillars of Our Strategy: Supply Chain
Key Pillars of Our Strategy Supply Chain Infrastructure Double manufacturing infrastructure Develop “customer focused” packaging solutions Increase Increase Teva’s Teva’s market Adjust the plant-product portfolio according to the market share share in in key strategic profiling key markets markets I
Slide 10: Operations – Global Presence
Operations – Global Presence ' ! $!$ @7 ) . ! ' ! $! & ! ' '( ) ( @7 ( , " : -/ $ $( & 2 - ./ ( $ : ' + ' ( ) * ! 0 ) : + $ -3 1/ 0 1 + ) " $1 $ 2 " % & % " # $ $ Employees A44777 ! BC577
Slide 11: Wide Range of Technologies
Wide Range of Technologies Tablets, Capsules, MR Tablets, Powders for suspension Pre-filled syringes, Vials, Ampoules, Infusion Bags, Nebules (BFS), Ophthalmics Metered Dose Inhalers (MDI’s) Metered Dose Powder Inhalers (MDPI’s) Breath Actuated Inhalers (BAI’s) Liquids, Creams & Ointments, Nasal spr
Slide 12: Unmatched Capacity – Foundation For Global Leadership
Unmatched Capacity – Foundation For Global Leadership Volume Produces Planned capacity to exceed 90B by 2012 Tabs/Caps ~90B ! Double Our Capacity * 22B 22B 15B June YTD 3B * Current pace ~44B/year 1995 2000 2005 2008 2012
Slide 13: Quality System Approach
Quality System Approach D ! =#= $ D ! =#= ' # * > ! =' <!1 ! = ( !!1 1 ! > ! $ ! F$ '* = !$ ' ! $ D ! = ' ! E! $$ $$ ! '! 1 > ! = '
Slide 14: Teva and Barr: Strong strategic fit with attractive economics
Teva and Barr Strong strategic fit with attractive economics Generic R&D capabilities Production infrastructure Women’s health segment Potential synergies: GR&D Pharmaceutical production Teva API Materials purchasing
Slide 15: Global Leadership
Global Leadership Double portfolio value and capacity of global core functions Maintain and enhance Enable EnableTeva Tevato towin winin inall all service leadership markets marketswhere wherewe we compete compete Separate from the pack – unmatched global generic resources
Slide 16: Thank You!
Thank You! 16 wits TEVA PHARMACEUTICAL INDUSTRIES LTD.
Teva Pharmaceutical Industries — Investor Day (September 2008) on 6ix